Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Christopher Cioffi"'
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 6, Pp 1255-1272 (2020)
Abstract Introduction Patients with plaque psoriasis experience a variety of signs and symptoms that can impact daily life, which may not be evaluated by clinician-reported outcomes. This study aimed to develop and assess the content validity of a ne
Externí odkaz:
https://doaj.org/article/9b8f58c755fc4cb3be22274dcb35744a
Autor:
Kristian Reich, Melinda Gooderham, Richard B. Warren, Veerle Vanvoorden, Cynthia Madden, Bruce Strober, Dirk De Cuyper, Andrew Blauvelt, Luke Peterson, Carle Paul, Christopher Cioffi, Mark Lebwohl, Richard G. Langley
Publikováno v:
New England Journal of Medicine. 385:142-152
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients with mode
Autor:
Richard B. Warren, Christopher Cioffi, Paul S. Yamauchi, Nancy Cross, Kim A. Papp, Kristian Reich, Dirk De Cuyper, Veerle Vanvoorden, Luke Peterson, Andrew Blauvelt, Richard G. Langley, Jerry Bagel, April W. Armstrong
Publikováno v:
New England Journal of Medicine. 385:130-141
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necros...
Autor:
Richard B. Warren, Christopher Cioffi, Veerle Vanvoorden, Kristian Reich, Yukari Okubo, April W. Armstrong, Joseph F. Merola, Mark Lebwohl, Kenneth B. Gordon, Richard G. Langley, Kim A. Papp, Andrew Blauvelt, Cynthia Madden, Maggie Wang
Publikováno v:
The Lancet. 397:487-498
There is an unmet need for a treatment for psoriasis that results in complete skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. We aimed to c
Publikováno v:
Dermatology and Therapy
Dermatology and Therapy, Vol 10, Iss 6, Pp 1255-1272 (2020)
Dermatology and Therapy, Vol 10, Iss 6, Pp 1255-1272 (2020)
Introduction Patients with plaque psoriasis experience a variety of signs and symptoms that can impact daily life, which may not be evaluated by clinician-reported outcomes. This study aimed to develop and assess the content validity of a new patient
Autor:
Luke Peterson, Alice B. Gottlieb, Joseph F. Merola, Christopher Cioffi, Llenalia Garcia, Christopher Pelligra, Richard B. Warren, Valerie Ciaravino
Publikováno v:
Dermatology and Therapy
Introduction Plaque psoriasis can significantly impact patients’ quality of life. We assessed psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), developed to capture patients’ experiences of signs, symptoms and impacts
Autor:
Mark Lebwohl, Kamran Ghoreschi, Bruce Strober, Kilian Eyerich, Jennifer Cather, Maggie Wang, Christopher Cioffi, Delphine Deherder, Fabienne Staelens, Natalie Nunez Gomez, Luis Puig
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB145
Autor:
Andrew Blauvelt, Mark Lebwohl, Alice Gottlieb, Matthias Augustin, Luis Puig, Paolo Eusebi, Christopher Cioffi, Balint Szilagyi, Susanne Wiegratz, Lars Iversen
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB152
Autor:
Matthias Augustin, Alice B. Gottlieb, Llenalia Garcia, Christopher Pelligra, Luke Peterson, Valerie Ciaravino, Christopher Cioffi, Richard B. Warren
Publikováno v:
Advances in Therapy
Introduction This analysis assessed the psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome (PRO) tool designed to capture patient experiences of the signs, symptoms and impacts of psoriasis
Autor:
Peter Foley, Richard B. Warren, Luke Peterson, Eva Cullen, Christopher Cioffi, Melinda Gooderham, Cynthia Madden, April Armstrong, Bruce Strober, Diamant Thaçi, Cristina Bulai Livideanu
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A360-A361